ProtAffin AG Granted Patent in EU for CellJammer(R) Discovery Technology  
3/14/2011 10:18:29 AM

GRAZ, Austria & OXFORD, England--(BUSINESS WIRE)--ProtAffin AG, a biotechnology company developing novel biopharmaceuticals for respiratory disease, inflammation and oncology, today announced that it has been granted a key patent by the European Patent Office protecting its CellJammer® discovery technology, which enables the development of a new class of biopharmaceuticals. The Company has initially applied this technology to chemokines, a large class of pro-inflammatory and pro-migratory proteins, which can be modified using the technology, converting them into anti-inflammatory decoy proteins. The company’s lead program based on this technology is PA401, a first-in-class biological that is in pre-clinical development for COPD and other lung diseases where neutrophils cause chronic lung damage.